Начало › Метастатичен рак › Северна Каролина › Durham
Клинични проучвания за Метастатичен рак в Durham, NC
33 проучвания за Метастатичен рак търсят участници в обекти в и около Durham (в радиус от около 30 мили). Отворете проучването, за да видите кой може да участва и как да се свържете с екипа.
Официален текст на проучването (английски)
Търсите участници за проучване? Представяме го в началото на тази страница — $99 за 30 дни →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
Набиране на участнициФаза 1/2
- Avenzo Therapeutics Recruiting Site, Chapel Hill · на 10 мили
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Набиране на участнициФаза 2
- Duke University Medical Center, Durham
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Набиране на участнициФаза 1/2
- Duke University, Durham
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Набиране на участнициФаза 2/3
- Duke University Medical Center, Durham
- University of North Carolina at Chapel Hill, Chapel Hill · на 10 мили
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
Набиране на участнициФаза 3
- Duke Cancer Center - Investigational Chemotherapy Service, Durham
- Duke Cancer Center, Durham
- Duke University Hospital - Vascular Interventional Radiology, Durham
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Набиране на участнициФаза 2
- Duke Cancer Institute, Durham
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
Набиране на участнициФаза 2/3
- UNC Hospitals, The University of North Carolina at Chapel Hill, Chapel Hill · на 10 мили
- University of North Carolina Hospitals at Hillsborough, Hillsborough · на 13 мили
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Набиране на участнициФаза 3
- Duke Cancer Institute, Durham
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Набиране на участнициФаза 3
- University of North Carolina Medical Center, Chapel Hill · на 10 мили
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Набиране на участнициФаза 3
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · на 10 мили
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Набиране на участнициФаза 1
- University of North Carolina (UNC) - Chapel Hill, Chapel Hill · на 10 мили
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1/2
- Duke University, Durham
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
Набиране на участници
- Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill · на 10 мили
A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)
Набиране на участнициФаза 1
- Duke Cancer Center, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
Набиране на участнициФаза 1
- Research Site, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Набиране на участнициФаза 1
- Research Site, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Набиране на участнициФаза 1
- Duke Cancer Center, Durham
A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Набиране на участнициФаза 1/2
- Duke University Medical Center, Durham
UNC Childhood, Adolescent, and Young Adult Cancer Cohort
Набиране на участнициНаблюдателно проучване
- University of North Carolina at Chapel Hill, Chapel Hill · на 10 мили
UNC Metastatic Cancer Radiation Therapy Registry
Набиране на участнициНаблюдателно проучване
- Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill, Chapel Hill · на 10 мили
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
Набиране на участнициФаза 1/2
- University of North Carolina at Chapel Hill, Chapel Hill · на 10 мили
Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
Набиране на участнициФаза 2/3
- Durham VA Medical Center, Durham, NC, Durham
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
Набиране на участнициФаза 2/3
- Duke University Medical Center, Durham
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Набиране на участнициФаза 1/2
- Duke Cancer Center/ DUMC, Durham
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
Набиране на участнициФаза 1
- Duke Cancer Institute, Durham
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
Набиране на участнициФаза 3
- Duke University, Durham
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
Набиране на участнициНаблюдателно проучване
- Durham Veterans Administration Health Care System (DVAHCS), Durham
- Duke University Medical Center, Durham
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Набиране на участнициФаза 1
- Duke Cancer Center, Durham
ONC201 and Atezolizumab in Obesity-Driven Endometrial Cancer
Набиране на участнициФаза 1
- Lineberger Comprehensive Cancer Center, Chapel Hill · на 10 мили
JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors
Набиране на участнициФаза 1
- Duke University Medical Center - Duke Cancer Institute, Durham
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Набиране на участнициНаблюдателно проучване
- Massive Bio SYNERGY-AI site, Chapel Hill · на 10 мили
A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s)
Набиране на участнициФаза 3
- Duke University - Trent Center, Durham
A Study of NX-1607 in Adults With Advanced Malignancies
Набиране на участнициФаза 1
- University of North Carolina, Chapel Hill · на 10 мили
Проучвания за Метастатичен рак в други градове
- Houston, TX104 проучвания
- New York City, NY93 проучвания
- Nashville, TN70 проучвания
- Boston, MA63 проучвания
- Los Angeles, CA57 проучвания
- St. Louis, MO54 проучвания
- Arlington, VA53 проучвания
- Philadelphia, PA46 проучвания
- Chicago, IL45 проучвания
- San Antonio, TX44 проучвания
- Washington, DC43 проучвания
- Dallas, TX42 проучвания
Други проучвания в Durham
- Рак на гърдата64 проучвания
- Рак (всички видове)58 проучвания
- Рак на белия дроб с недребноклетъчен тип39 проучвания
- Множествен миелом37 проучвания
- Остра миелоидна левкемия33 проучвания
- Рак на простатата32 проучвания
- Рак на белия дроб32 проучвания
- Колоректален рак28 проучвания
- Рак на яйчниците27 проучвания
- Хронична лимфоцитна левкемия27 проучвания
- Сърдечна недостатъчност26 проучвания
- Рак на панкреаса24 проучвания
От ClinicalTrials.gov, данни към 6.10.2026 г.. Всяко проучване има свои критерии за участие; екипът на проучването определя кой може да се включи.